- (anti-IFN-aR)
nirsevimab (anti-RSV)
MedImmune, Inc. v. Genentech, Inc. "12
years on,
Astra draws a line
under Medimmune". Evaluate.com. 2019-02-14. Retrieved...
-
Cambridge Antibody Technology (in 2006),
MedImmune (in 2007),
Spirogen (in 2013) and
Definiens (by
MedImmune in 2014). It has its
research and development...
-
patents cover Medimmune's processes for
generating the
collections of
human antibody genes that
comprise MedImmune Cambridge libraries.
MedImmune has patents...
-
March 2018,
Compugen entered into an
exclusive license agreement with
MedImmune, the
global biologics research arm of
AstraZeneca to
develop bi-specific...
-
Tetra in the
European Union.
FluMist was
first introduced in 2003 by
MedImmune. In the
United States,
FluMist is
approved for self- or caregiver-administration...
-
actual controversy was most
recently addressed by the
Supreme Court in
MedImmune, Inc. v. Genentech, Inc., 549 U.S. 118 (2007). But even if an
actual controversy...
- capsule". Daily
Med. 4
March 2022.
Retrieved 16
December 2022. "Zegerid OTC-
omeprazole and
sodium bicarbonate capsule,
gelatin coated". Daily
Med. 5 December...
-
Retrieved 1
April 2024. "Farxiga-
dapagliflozin tablet, film coated". Daily
Med.
National Institutes of Health,
National Library of Medicine, U.S. Department...
-
acquired by AstraZeneca, who also
acquired MedImmune,
combining the two into a
biologics division.
MedImmune renamed CAT-8015 to
moxetumomab pasudotox...
-
Genomics company, the J.
Craig Venter Institute, and
AstraZeneca (formerly
MedImmune).
Maryland is home to
defense contractor Emergent BioSolutions, which...
